C) ROBOT-ASSISTED (Da Vinci) RADICAL PROSTATECTOMY – 28/04/2025 On 08/05/2025, I had the urinary catheter removed....

Your Post-Surgical Pathology & Follow-Up Strategy

Congratulations on your successful surgery and excellent early recovery! I can see you've had a robot-assisted radical prostatectomy on [date removed], and your pathology report confirms what your surgical team indicated — favorable findings with some important nuances to understand. Let me break down what your final pathology means and what to expect in your follow-up.

---

Understanding Your Final Surgical Pathology

Your pathology report reveals important details that affect your prognosis and follow-up plan:

The Good News (Favorable Findings):

| Finding | Your Result | Clinical Significance | |---------|-----------|----------------------| | Surgical Margins | NEGATIVE (clean) | Cancer did NOT extend to the edge of removed tissue — excellent sign | | Seminal Vesicles | FREE of cancer | No invasion into seminal vesicles | | Extraprostatic Extension | NO definite extension | Cancer stayed within prostate capsule | | Lymph Node Status | Nx (not assessed) | Standard for early-stage; no clinical evidence of node involvement | | Metastatic Disease | Mx (no evidence)** | No distant spread detected | | Pathological Stage | pT2 | Organ-confined disease — best possible stage after surgery |

Translation: Your cancer was completely removed, and it did not break through the prostate capsule. This is the most favorable scenario for early-stage prostate cancer.

---

The Important Detail (Margin Consideration):

Your report notes: "In the sections from the apex, cancerous elements are observed focally reaching the inked surgical margin."

What this means:

• At the apex (tip) of the prostate, cancer cells came very close to or touched the surgical margin
• This is called a focal positive margin or margin at risk
• However, this is NOT the same as a frankly positive margin (cancer clearly beyond the edge)

Clinical significance:

• This finding is relatively common in early-stage prostate cancer surgery
• It does NOT automatically mean you need additional treatment
• It does mean your follow-up PSA monitoring becomes especially important
• It may influence your oncologist's decision about adjuvant (additional) therapy

According to NCCN Guidelines, focal apical margins in pT2 disease with otherwise negative margins are typically managed with:

1. Close PSA surveillance (your current plan)
2. Consideration of adjuvant radiation therapy IF PSA rises (biochemical recurrence)
3. Observation alone if PSA remains undetectable

---

Your Bilateral Cancer Finding

Your pathology shows cancer in both lobes of the prostate:

• Right lobe: <5% involvement
• Left lobe: <5% involvement

What this tells us:

• This is not uncommon in prostate cancer — cancer is often multifocal
• The limited extent (<5% in each lobe) is favorable
• Your biopsy correctly identified the dominant lesion on the left
• The right-sided disease was clinically occult (not visible on imaging)

This reinforces why complete surgical removal was the right choice — it removed all disease, not just the visible lesion.

---

Gleason Score Confirmation: 3+4=7 (Grade Group 2)

Your final surgical specimen confirms the biopsy findings:

• 70% Gleason pattern 3 (well-formed glands)
• 30% Gleason pattern 4 (cribriform, fused, poorly defined glands)

What this means for prognosis:

• Grade Group 2 is intermediate-risk but on the favorable end of intermediate
• The predominance of pattern 3 (70%) is favorable
• The limited extent of pattern 4 (30%) is favorable
• Combined with pT2 stage, this suggests good long-term prognosis

According to NCCN data, men with pT2, Grade Group 2 prostate cancer who undergo radical prostatectomy have:

• 10-year biochemical recurrence-free survival: ~75-80%
• 10-year cancer-specific survival: >95%

---

Your Excellent Functional Outcomes

I want to highlight something important: You have had NO urinary incontinence since catheter removal on [date removed].

This is excellent news and suggests:

• Your surgeon had good nerve-sparing technique
• Your pelvic floor muscles are recovering well
• Your urinary sphincter function is intact

According to NCCN Guidelines, continence outcomes after robot-assisted radical prostatectomy in experienced centers:

• Continence at 3 months: 85-95% (you're already there!)
• Continence at 12 months: >95%

This puts you in a very favorable position for quality of life post-surgery.

---

Your PSA Follow-Up Schedule: What to Expect

Your surgical team has given you excellent guidance. Let me contextualize it with NCCN recommendations:

Recommended PSA Testing Timeline:

Phase 1: Early Surveillance (Months 1-24)

• First PSA: ~40 days post-op (early June 2025)
  • Should be undetectable (<0.05 ng/mL) or very low
  • Confirms complete surgical removal
• Then: Every 3 months for 2 years
  • Months 3, 6, 9, 12, 15, 18, 21, 24 post-op
  • Allows early detection of any rise

Phase 2: Extended Surveillance (Years 2-5)

• Every 6 months (less frequent, but still close monitoring)
• Continues to watch for delayed recurrence

Phase 3: Long-term Follow-up (Year 5+)

• Annually (if PSA remains undetectable)
• Lifelong monitoring recommended

What "Undetectable" Means:

After radical prostatectomy, your PSA should drop to undetectable levels (<0.05 ng/mL or lower, depending on assay sensitivity).

Why this matters:

• Confirms complete removal of prostate tissue
• Establishes your PSA nadir (lowest point)
• Any subsequent rise above nadir = biochemical recurrence (BCR)

---

Understanding Biochemical Recurrence (BCR) Risk

Given your focal apical margin, you have a slightly elevated risk of BCR compared to men with completely negative margins. However, your risk is still favorable because:

✅ pT2 stage (organ-confined)
✅ Grade Group 2 (intermediate, not high-risk)
✅ <5% involvement in each lobe (limited extent)
✅ Negative seminal vesicles
✅ No extraprostatic extension

Estimated BCR risk at 5 years: ~15-25% (varies by series)

Important context: BCR does NOT mean cancer has returned to your body — it means PSA is detectable again, which may indicate:

• Microscopic residual disease at the surgical margin
• Occult metastatic disease (less likely given your staging)
• Recurrence in the prostate bed (if you had radiation)

---

What to Do If Your PSA Rises (Biochemical Recurrence)

This is important to understand before it happens, so you're prepared:

Scenario 1: PSA Rises Early (Within 1-2 Years)

If detected:

• Suggests possible margin-positive disease or aggressive biology
• Your oncologist will likely recommend:
  • PSMA-PET scan (highly sensitive imaging to find where cancer is)
  • Salvage radiation therapy to the prostate bed (if PSMA-PET negative)
  • Possibly hormone therapy (ADT) combined with radiation

According to NCCN Guidelines:

• Early BCR (within 2 years) warrants aggressive treatment
• Salvage radiation therapy is most effective when PSA is <0.5 ng/mL
• Combined with ADT, it improves outcomes significantly